What is the recommended dosing for hydralazine (Hydralazine) in treating hypertension and heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hydralazine Dosing Guidelines for Hypertension and Heart Failure

For hypertension management, hydralazine should be initiated at 10-25mg three times daily and titrated to a target dose of 75mg three times daily (100-200mg daily in divided doses), while for heart failure, the recommended starting dose is 37.5mg hydralazine with 20mg isosorbide dinitrate three times daily, titrated to a target of 75mg hydralazine with 40mg isosorbide dinitrate three times daily. 1

Dosing for Hypertension

Initial Dosing and Titration

  • Starting dose: 10-25mg orally three times daily 1
  • Gradual titration: Increase by 10mg increments every 2-4 weeks 1
  • Target dose: 100-200mg daily in 2-3 divided doses 1
  • Maximum dose: Up to 75mg three times daily for resistant hypertension 1

Administration Considerations

  • Taking with food results in higher plasma levels 2
  • For once-daily dosing, slow-release formulations are preferred over conventional tablets, as conventional tablets show waning effect at 24 hours 3
  • Twice-daily dosing with conventional tablets provides satisfactory 24-hour control 3

Dosing for Heart Failure

Fixed-Dose Combination with Isosorbide Dinitrate

  • Initial dose: 37.5mg hydralazine/20mg isosorbide dinitrate three times daily 4, 1
  • Target dose: 75mg hydralazine/40mg isosorbide dinitrate three times daily 4, 1
  • Consider dose up-titration after 2-4 weeks if tolerated 4

Patient Selection

  • Particularly beneficial in self-identified Black patients with HFrEF who remain symptomatic despite standard therapy 4, 1
  • Alternative for patients who cannot tolerate ACE inhibitors or ARBs 4
  • Should not replace ACE inhibitors/ARBs in patients who tolerate these medications 4

Intravenous Dosing for Hypertensive Emergencies

  • Initial dose: 10mg via slow IV infusion (maximum initial dose 20mg) 1
  • Frequency: Repeat every 4-6 hours as needed 1
  • Conversion ratio: 2:1 (oral:IV) when transitioning between routes 1
  • Continuous blood pressure monitoring required during IV administration 1

Monitoring and Dose Adjustments

Blood Pressure Monitoring

  • Monitor BP after each dose increase 1
  • For IV administration, continuous monitoring is essential 1
  • Goal for hypertensive emergencies: Reduce SBP by no more than 25% within first hour, then to 160/100 mmHg within 2-6 hours, and normalize over 24-48 hours 1

Special Populations

  • Elderly patients may require lower IV doses due to increased sensitivity 1
  • Pediatric dosing (though not established in controlled trials): Starting dose 0.75mg/kg daily in four divided doses, gradually increasing to maximum 7.5mg/kg or 200mg daily 2
  • Patients with renal impairment (CCr <35ml/min) may require less frequent dosing due to prolonged duration of action (14.3 hours vs 7.9 hours in normal renal function) 5
  • Acetylator status affects dosing requirements: fast acetylators may require higher doses (D50 of 1.68mg/kg vs 0.87mg/kg for slow acetylators) 6

Common Side Effects and Management

Side Effects to Monitor

  • Reflex tachycardia and fluid retention (consider combination with beta-blockers and diuretics) 1
  • Headache, dizziness, flushing, and gastrointestinal complaints 4, 1
  • Drug-induced lupus-like syndrome with higher doses (>100mg daily) or long-term use 1
  • Symptomatic hypotension (dizziness, lightheadedness) 4, 1

Combination Therapy

  • Combining with beta-blockers helps counteract reflex tachycardia 1, 7
  • Combining with diuretics helps manage fluid retention 1
  • For heart failure, combination with isosorbide dinitrate has shown mortality benefit (43% relative risk reduction) 4

Practical Considerations

  • Poor adherence may occur due to multiple daily doses and side effects 4
  • Consider slower titration to enhance tolerance if side effects occur 4
  • For patients with inadequate response to 100mg, doses of 150-200mg may be effective 5
  • Hydralazine with isosorbide dinitrate has shown significant reduction in heart failure hospitalizations (33% relative risk reduction) 4

References

Guideline

Hydralazine Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Hydralazine once daily in hypertension.

British medical journal (Clinical research ed.), 1982

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Hemodynamic evaluation of hydralazine dosage in refractory heart failure.

Clinical pharmacology and therapeutics, 1980

Research

Hydralazine dose-response curve analysis.

Journal of pharmacokinetics and biopharmaceutics, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.